Rib Raising for Post-operative Ileus
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03662672 |
|
Recruitment Status :
Completed
First Posted : September 7, 2018
Last Update Posted : March 10, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Intestinal Pseudo-Obstruction Manipulation, Osteopathic Postoperative Care Postoperative Nausea and Vomiting Postoperative Complications Osteopathic Medicine | Procedure: Rib raising and lumbar release Procedure: Sham procedure | Not Applicable |
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 102 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Double (Participant, Care Provider) |
| Primary Purpose: | Treatment |
| Official Title: | Randomized Controlled Trial of Rib Raising as Early Treatment for Post-operative Ileus |
| Actual Study Start Date : | September 27, 2018 |
| Actual Primary Completion Date : | August 15, 2019 |
| Actual Study Completion Date : | August 30, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Rib-raising Intervention
We will do daily rib raising and lumbar release from the 5th thoracic vertebra to the 2nd lumbar vertebra for 2 minutes per side for rib raising and 2 minutes for lumbar release.
|
Procedure: Rib raising and lumbar release
Rib raising per protocol described in arm description. |
|
Sham Comparator: Sham Intervention
We will do daily sham intervention from the 5th thoracic vertebra to the 2nd lumbar vertebra where we place our hands under the ribs for 2 minutes per side and under the lumbar area for 2 minutes without applying any pressure (or applying pressure into the bed).
|
Procedure: Sham procedure
Sham procedure per protocol described in arm description |
- Length of Stay [ Time Frame: 0-14 days ]
- Time to first meal [ Time Frame: 0-14 days ]
- Time to first flatus [ Time Frame: 0-14 days ]
- Time to first bowel movement [ Time Frame: 0-14 days ]
- Need for nasogastric tube postop [ Time Frame: 0-14 days ]
- Nausea/vomiting postop [ Time Frame: 0-14 days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 69 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Major abdominal surgery (laparotomy, laparoscopy excluding simple laparoscopic appendectomy or laparoscopic cholecystectomy)
Exclusion Criteria:
- Open abdomen for >72 hours
- Prior history of major post-operative complications
- Intolerance to anesthesia
- Co-morbidities including osteoporosis and osteopenia
- Spine or rib fractures
- Pregnancy
- Prisoners
- History of osteopathic manipulation
- Recruitment delayed beyond 48 hours
- Surgeon requested exclusion
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03662672
| United States, New Jersey | |
| University Hospital | |
| Newark, New Jersey, United States, 07103 | |
| Responsible Party: | Nina Elizabeth Glass, MD, Assistant Professor, Rutgers, The State University of New Jersey |
| ClinicalTrials.gov Identifier: | NCT03662672 |
| Other Study ID Numbers: |
Pro2018001548 |
| First Posted: | September 7, 2018 Key Record Dates |
| Last Update Posted: | March 10, 2022 |
| Last Verified: | March 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Undecided |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Intestinal Pseudo-Obstruction Vomiting Postoperative Complications Postoperative Nausea and Vomiting Nausea Signs and Symptoms, Digestive |
Pathologic Processes Ileus Intestinal Obstruction Intestinal Diseases Gastrointestinal Diseases Digestive System Diseases |

